Abstract
7 Highly polar, water-soluble prodrugs of the HIV protease inhibitor amprenavir: A new approach toward a more compact dosing regimen : A. Spaltenstein 1, C. Baker 2, Y. Graynunez 1, I. Kaldor 1, W. Kazmierski 1, D. Reynolds 1, R. Tung 2, P. Wheelan 1, E. Furfine 1 1Glaxo Wellcome Inc., Res. Triangle Park, NC, USA and 2Vertex Pharmaceuticals, Cambridge,
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
